SUMMARY In view of the claim that alclofenac has a specific antirheumatoid action a detailed biochemical study has been made over a 6-month period of 2 groups of patients with rheumatoid arthritis receiving either alclofenac or D-penicillamine for the first time. We found no biochemical evidence and little clinical evidence that alclofenac had a 'penicillamine-like' effect in rheumatoid arthritis.
Alclofenac* (4-allyloxyl-3-chlorophenylacetic acid) is a nonsteroidal anti-inflammatory agent derived from arylacetic acid. Biochemical studies have suggested, however, that this drug may have a more specific action in rheumatoid arthritis, fundamentally influencing the disease process. This evidence comes from fall in erythrocyte sedimentation rate (ESR)," 2 fall in immunoglobulins and latex agglutination titre but not in sheep cell agglutination test (SCAT) titre,3 rise in free plasma tryptophan,' and a rise in serum sulphydryl levels. 4 As part of a long-term study in which we are attempting to define biochemical profiles of response in patients with rheumatoid arthritis treated for the first time with 'specific' drugs we have compared the majority of these biochemical changes in patients treated either with D-penicillamine or with alclofenac. We report these results, which are at variance with those previously described.
Patients and methods
All patients had classical or definite rheumatoid arthritis (American Rheumatism Association criteria) and moderate or severe disease activity judged by the presence of at least 3 out of: (i) tenderness of 6 weeks of alclofenac treatment. Reasons for withdrawal were skin rash 2, lack of effect 1, noncompliance 2, and severe diarrhoea apparently induced by alclofenac in a seropositive patient 1.
The majority of biochemical variables showed significant improvement with D-penicillamine but not with alclofenac. Fig. 1 shows changes in erythrocyte sedimentation rate, plasma viscosity, C-reactive protein, and total serum sulphydryl levels for the 2 drugs. Levels The majority of clinical variables showed improvement with D-penicillamine, not seen with alclofenac This was most marked with articular index, which showed a significant improvement by week 16 (P<0-01) and thereafter, whereas change with alclofenac did not show significant improvement. Change in summated change scale was also marked on D-penicillamine, though grip strength showed little change on either drug.
A striking difference was also observed between the 2 correlation matrices (Tables 1 and 2 ). Levels of significance for D-penicillamine were not only of higher order but also more frequently seen than those obtained with alclofenac.
Discussion
Although we are reluctant to draw clinical conclusions from a study in which entry was not strictly randomised, this study suggests that alclofenac did not produce the long-term clinical benefit seen with D-penicillamine. The high drop-out rate in the alclofenac treated group prevented satisfactory statistical between-group comparison towards the end of the study. Nevertheless, it appears that mean patient data for the relatively small alclofenac group remained approximately constant instead of showing the steady serial change seen with D-penicillamine.
Our study failed to confirm some ofthe biochemical 
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If a drug has a fundamental action on the disease process it would be reasonable to expect simultaneous improvement in both clinical and biochemical parameters and thus a significant correlation between them. Comparison of correlation matrices for different drugs is therefore a meaningful screen on small groups of patients for possible longterm antirheumatoid activity in novel compounds. Moreover, it will not be biased by patient drop-out. It is, however, necessary to confirm that the compound under test does not make the disease significantly worse. A clear difference emerges between the correlation matrices for these 2 drugs, and our unpublished data on comparable matrices obtained from patients treated with hydroxychloroquine and gold support the validity of this comparative approach. On this basis, as well as on review of the observed clinical and biochemical changes, we have found no evidence over a 6-month period to support the view that alclofenac has a specific antirheumatoid effect. Moreover patient tolerance of this drug was poorer than for D-penicillamine. 
